Literature DB >> 7400304

Effects of parathyroid hormone infusion and primary hyperparathyroidism on serum prolactin in man.

J H Castro, J F Caro, H J Kim, J A Glennon.   

Abstract

Serum PRL, parathyroid hormone (PTH), and Ca levels were measured in 14 patients (8 women and 6 men) with primary hyperparathyroidism. Six normal volunteers (3 men and 3 women) received a 1-h control infusion of 5% glucose containing 2% human serum albumin, a 1-h infusion of the same fluid containing 450 U bovine PTH, and a repeated 1-h infusion of glucose and albumin. Serum PRL was measured during these infusion periods and showed a peak within 30 min of the start of bovine PTH infusion; PRL levels declined therafter in spite of continued PTH infusion. Serum PRL levels returned to normal within 1 h of discontinuance of bovine PTH infusion. The serum PRL levels in patients with primary hyperparathyroidism were within the normal range, and there was no correlation between serum PTH and PRL levels. These results suggest that the PRL response to PTH infusion is a pharmacological rather than a physiological or pathophysiological effect of PTH.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7400304     DOI: 10.1210/jcem-51-2-397

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  3 in total

Review 1.  Drug-induced changes in prolactin secretion. Clinical implications.

Authors:  K Hell; H Wernze
Journal:  Med Toxicol Adverse Drug Exp       Date:  1988 Nov-Dec

2.  Prolactin and calcium metabolism: influence of hyperprolactinemia on immunoreactive parathyroid hormone levels in man and in the rat.

Authors:  C E Fiore; R D'Agata; G Clementi; L S Malatino
Journal:  J Endocrinol Invest       Date:  1984-12       Impact factor: 4.256

3.  Increased forearm bone mineral content after bromocriptine treatment in hyperprolactinemia.

Authors:  M P Caraceni; E Corghi; S Ortolani; S Casazza; A D'Alberton; T Motta
Journal:  Calcif Tissue Int       Date:  1985-12       Impact factor: 4.333

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.